Related Experiment Video
Updated: Feb 12, 2026

Application of CRISPR Interference CRISPRi for Gene Silencing in Pathogenic Species of Leptospira
Published on: August 14, 2021
RNA Interference-Mediated Gene Silencing in Esophageal Adenocarcinoma
Farhadul Islam1,2, Vinod Gopalan1, Alfred K Lam3
1Cancer Molecular Pathology of School of Medicine, Griffith University, Gold Coast, Australia.
Abstract:
RNA interference (RNAi) is a normal physiological mechanism in which a short effector antisense RNA molecule regulates target gene expression. It is a powerful tool to silence a particular gene of interest in a sequence-specific manner and can be used to target against various molecular pathways in esophageal adenocarcinoma by designing RNAi targeting key pathogenic genes. RNAi-based therapeutics against esophageal adenocarcinoma can be developed using different strategies including inhibition of overexpressed oncogenes, blocking cell division by interfering cyclins and related genes or enhancing apoptosis by suppressing anti-apoptotic genes. In addition, RNAi against multidrug resistance genes or chemo-resistance targets may provide promising cancer therapeutic options. Here, we describe RNAi technology using MET, a proto-oncogene in esophageal adenocarcinoma cells, as a model target. Lentiviral particles expressing MET shRNA was used to silence MET genes. Then, Western blot analysis was performed to confirm MET knockdown.
Insights
RNA interference (RNAi) effectively silences genes in esophageal adenocarcinoma. This study demonstrates RNAi
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- RNA interference (RNAi) is a natural gene regulation process.
- RNAi offers targeted gene silencing for therapeutic strategies.
- Esophageal adenocarcinoma involves complex molecular pathways.
Purpose of the Study:
- To explore RNAi technology for esophageal adenocarcinoma treatment.
- To utilize MET, a proto-oncogene, as a model target for RNAi.
- To demonstrate sequence-specific gene silencing in cancer cells.
Main Methods:
- Designing RNAi constructs targeting key pathogenic genes.
- Utilizing lentiviral particles for gene delivery.
- Employing short hairpin RNA (shRNA) to silence MET genes.
- Confirming gene knockdown via Western blot analysis.
Main Results:
- Successful silencing of MET proto-oncogene in esophageal adenocarcinoma cells.
- Demonstrated efficacy of RNAi in targeting specific genes.
- Validated Western blot as a method for confirming gene knockdown.
Conclusions:
- RNAi is a viable therapeutic strategy for esophageal adenocarcinoma.
- Targeting oncogenes like MET with RNAi shows promise.
- Further development of RNAi-based cancer therapeutics is warranted.
Related Concept Videos
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Organization of Genes
RNA Polymerase II Accessory Proteins
Interference and Diffraction
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Esophageal Varices-I: Introduction

